Company profile
Telomir Pharmaceuticals, Inc.
NASDAQ:TELOBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07581314 | phase1_2 | not_yet_recruiting | 2026-10-01 | 2027-05-01 | Telomir Pharmaceuticals, Inc. | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) |
FDA applications (0)
No records yet.